- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Complement 3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN)
- Meeting Date: July 2026
Pegcetacoplan – July 2026
- Solution for subcutaneous infusion 1,080 mg in 20 mL
Public Summary Documents
Last updated
13 November 2026
